Modality
Fusion Protein
MOA
GLP-1/GIP
Target
JAK2
Pathway
Tau
RSV
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
~Jan 2023
→ ~Apr 2024
Phase 2
Jul 2024
→ Sep 2030
Phase 2Current
NCT04087058
939 pts·RSV
2024-07→2030-09·Terminated
939 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-217mo awayPh1 Dose Esc· RSV
2030-09-164.5y awayPh3 Readout· RSV
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Termina…
Catalysts
Ph1 Dose Esc
2026-10-21 · 7mo away
RSV
Ph3 Readout
2030-09-16 · 4.5y away
RSV
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04087058 | Phase 2/3 | RSV | Terminated | 939 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 | |
| IRO-8712 | Disc Medicine | Preclinical | JAK2 |